Antiparasitic Drugs Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Form, End User, Functionality, Mode, Stage

Description

The global Antiparasitic Drugs Market is projected to grow from $24.0 billion in 2025 to $40.6 billion by 2035, at a compound annual growth rate (CAGR) of 5.4%. The antiparasitic drugs market is characterized by the presence of global pharmaceutical and animal-health companies alongside regional manufacturers, with competition centered on product portfolios, formulation capabilities, regulatory approvals, and distribution reach. Key products include anthelmintics, antiprotozoals, ectoparasiticides, and endoparasiticides supplied through oral, topical, injectable, and other formulations for human and veterinary applications. Companies are also expanding parasite-control offerings across livestock and companion-animal healthcare. For instance, in June 2026, Merck Animal Health reaffirmed its commitment to combating the New World screwworm threat through collaboration, education, and innovative medicines for parasite prevention and treatment, highlighting continued industry focus on parasitic disease management.

Based on product, tablets are the dominant segment in the antiparasitic drugs market. Tablets are widely used because they provide convenient oral administration, consistent dosing, ease of storage, and suitability for various antiparasitic treatments. They are commonly used across human and veterinary applications for managing parasitic infections and are available in multiple strengths and formulations. Tablets can also support routine treatment and preventive dosing, making them suitable for use across hospitals, clinics, veterinary clinics, and other healthcare settings. Their established manufacturing processes, broad availability, and familiarity among healthcare professionals and patients further contribute to their leading position within the product segment.

Market Segmentation
Type	Anthelmintics, Antiprotozoals, Ectoparasiticides, Endoparasiticides, Others
Product	Tablets, Capsules, Injectables, Topical Solutions, Suspensions, Powders, Others
Technology	Synthetic, Biological, Others
Application	Human Health, Veterinary, Agriculture, Aquaculture, Others
Form	Solid, Liquid, Semi-solid, Others
End User	Hospitals, Clinics, Veterinary Clinics, Research Institutes, Pharmaceutical Companies, Others
Functionality	Curative, Preventive, Others
Mode	Prescription, Over-the-Counter, Others
Stage	Discovery, Preclinical, Clinical Trials, Commercialized, Others

Based on application, veterinary is the fastest-growing segment in the antiparasitic drugs market. Antiparasitic drugs are widely used in veterinary care to prevent and treat parasitic infections affecting livestock, companion animals, and other animals. These products include treatments for internal and external parasites and are administered through various formulations according to animal species and treatment requirements. Veterinary applications cover both routine parasite control and therapeutic interventions, with products used through veterinary clinics, farms, and animal healthcare services. The segment includes medicines designed for different animal groups and infection types, supporting its expanding role within the overall antiparasitic drugs market.

Geographical Overview

North America is the largest region in the antiparasitic drugs market, supported by established healthcare infrastructure, broad access to pharmaceutical products, and significant demand across human and veterinary healthcare. The United States represents the major market within the region, supported by its large pharmaceutical industry, extensive veterinary sector, and established distribution networks. Canada also contributes to regional demand through human and animal healthcare applications. The presence of major pharmaceutical and animal-health companies, ongoing product development, and established treatment practices for parasitic infections further support the region's leading position in the global antiparasitic drugs market.

Asia-Pacific is the fastest-growing region in the antiparasitic drugs market, supported by its large population, considerable burden of parasitic diseases, expanding healthcare access, and growing pharmaceutical manufacturing capabilities. China and India are major markets, with increasing demand across human healthcare, veterinary medicine, agriculture, and aquaculture. Improvements in healthcare infrastructure and greater availability of pharmaceutical treatments are supporting market development across emerging economies. The region also has substantial livestock and agricultural activities, creating demand for antiparasitic products used in animal health and parasite management. Increasing healthcare awareness and expanding pharmaceutical distribution networks further support regional market growth.

Key Trends and Drivers

Adoption of Combination Therapies

The antiparasitic drugs market is witnessing increasing adoption of combination therapies that use multiple active ingredients to address parasitic infections. These therapies can provide broader treatment coverage and support the management of infections involving different parasite types or life-cycle stages. Combination approaches are being incorporated into treatment strategies for diseases such as malaria and other parasitic infections where multiple therapeutic mechanisms may be required. Pharmaceutical companies are developing and evaluating combination formulations to improve treatment effectiveness, simplify dosing, and support efforts to manage drug resistance. This is contributing to greater availability of combination-based antiparasitic treatment options.

Rising Prevalence of Parasitic Infections

The rising prevalence of parasitic infections is driving demand for antiparasitic drugs across human and veterinary healthcare. Parasitic diseases such as malaria, helminthiasis, and other protozoal infections continue to require medical treatment, particularly in regions where sanitation, healthcare access, and disease-control infrastructure remain limited. In veterinary applications, parasitic infections also affect livestock and companion animals, creating demand for preventive and curative treatments. Increasing disease surveillance, diagnosis, and awareness is supporting treatment uptake, while pharmaceutical companies continue developing products for different parasite types and infection settings, strengthening demand across the antiparasitic drugs market.

Research Scope

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

Product Code: GIS26940

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Application
2.4 Key Market Highlights by End User
2.5 Key Market Highlights by Form
2.6 Key Market Highlights by Technology
2.7 Key Market Highlights by Mode
2.8 Key Market Highlights by Stage
2.9 Key Market Highlights by Functionality

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Anthelmintics
- 4.1.2 Antiprotozoals
- 4.1.3 Ectoparasiticides
- 4.1.4 Endoparasiticides
- 4.1.5 Others
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Tablets
- 4.2.2 Capsules
- 4.2.3 Injectables
- 4.2.4 Topical Solutions
- 4.2.5 Suspensions
- 4.2.6 Powders
- 4.2.7 Others
4.3 Market Size & Forecast by Application (2020-2035)
- 4.3.1 Human Health
- 4.3.2 Veterinary
- 4.3.3 Agriculture
- 4.3.4 Aquaculture
- 4.3.5 Others
4.4 Market Size & Forecast by End User (2020-2035)
- 4.4.1 Hospitals
- 4.4.2 Clinics
- 4.4.3 Veterinary Clinics
- 4.4.4 Research Institutes
- 4.4.5 Pharmaceutical Companies
- 4.4.6 Others
4.5 Market Size & Forecast by Form (2020-2035)
- 4.5.1 Solid
- 4.5.2 Liquid
- 4.5.3 Semi-solid
- 4.5.4 Others
4.6 Market Size & Forecast by Technology (2020-2035)
- 4.6.1 Synthetic
- 4.6.2 Biological
- 4.6.3 Others
4.7 Market Size & Forecast by Mode (2020-2035)
- 4.7.1 Prescription
- 4.7.2 Over-the-Counter
- 4.7.3 Others
4.8 Market Size & Forecast by Stage (2020-2035)
- 4.8.1 Discovery
- 4.8.2 Preclinical
- 4.8.3 Clinical Trials
- 4.8.4 Commercialized
- 4.8.5 Others
4.9 Market Size & Forecast by Functionality (2020-2035)
- 4.9.1 Curative
- 4.9.2 Preventive
- 4.9.3 Others

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Application
  - 5.2.1.4 End User
  - 5.2.1.5 Form
  - 5.2.1.6 Technology
  - 5.2.1.7 Mode
  - 5.2.1.8 Stage
  - 5.2.1.9 Functionality
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Application
  - 5.2.2.4 End User
  - 5.2.2.5 Form
  - 5.2.2.6 Technology
  - 5.2.2.7 Mode
  - 5.2.2.8 Stage
  - 5.2.2.9 Functionality
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Application
  - 5.2.3.4 End User
  - 5.2.3.5 Form
  - 5.2.3.6 Technology
  - 5.2.3.7 Mode
  - 5.2.3.8 Stage
  - 5.2.3.9 Functionality
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Application
  - 5.3.1.4 End User
  - 5.3.1.5 Form
  - 5.3.1.6 Technology
  - 5.3.1.7 Mode
  - 5.3.1.8 Stage
  - 5.3.1.9 Functionality
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Application
  - 5.3.2.4 End User
  - 5.3.2.5 Form
  - 5.3.2.6 Technology
  - 5.3.2.7 Mode
  - 5.3.2.8 Stage
  - 5.3.2.9 Functionality
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Application
  - 5.3.3.4 End User
  - 5.3.3.5 Form
  - 5.3.3.6 Technology
  - 5.3.3.7 Mode
  - 5.3.3.8 Stage
  - 5.3.3.9 Functionality
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Application
  - 5.4.1.4 End User
  - 5.4.1.5 Form
  - 5.4.1.6 Technology
  - 5.4.1.7 Mode
  - 5.4.1.8 Stage
  - 5.4.1.9 Functionality
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Application
  - 5.4.2.4 End User
  - 5.4.2.5 Form
  - 5.4.2.6 Technology
  - 5.4.2.7 Mode
  - 5.4.2.8 Stage
  - 5.4.2.9 Functionality
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Application
  - 5.4.3.4 End User
  - 5.4.3.5 Form
  - 5.4.3.6 Technology
  - 5.4.3.7 Mode
  - 5.4.3.8 Stage
  - 5.4.3.9 Functionality
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Application
  - 5.4.4.4 End User
  - 5.4.4.5 Form
  - 5.4.4.6 Technology
  - 5.4.4.7 Mode
  - 5.4.4.8 Stage
  - 5.4.4.9 Functionality
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Application
  - 5.4.5.4 End User
  - 5.4.5.5 Form
  - 5.4.5.6 Technology
  - 5.4.5.7 Mode
  - 5.4.5.8 Stage
  - 5.4.5.9 Functionality
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Application
  - 5.4.6.4 End User
  - 5.4.6.5 Form
  - 5.4.6.6 Technology
  - 5.4.6.7 Mode
  - 5.4.6.8 Stage
  - 5.4.6.9 Functionality
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Application
  - 5.4.7.4 End User
  - 5.4.7.5 Form
  - 5.4.7.6 Technology
  - 5.4.7.7 Mode
  - 5.4.7.8 Stage
  - 5.4.7.9 Functionality
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Application
  - 5.5.1.4 End User
  - 5.5.1.5 Form
  - 5.5.1.6 Technology
  - 5.5.1.7 Mode
  - 5.5.1.8 Stage
  - 5.5.1.9 Functionality
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Application
  - 5.5.2.4 End User
  - 5.5.2.5 Form
  - 5.5.2.6 Technology
  - 5.5.2.7 Mode
  - 5.5.2.8 Stage
  - 5.5.2.9 Functionality
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Application
  - 5.5.3.4 End User
  - 5.5.3.5 Form
  - 5.5.3.6 Technology
  - 5.5.3.7 Mode
  - 5.5.3.8 Stage
  - 5.5.3.9 Functionality
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Application
  - 5.5.4.4 End User
  - 5.5.4.5 Form
  - 5.5.4.6 Technology
  - 5.5.4.7 Mode
  - 5.5.4.8 Stage
  - 5.5.4.9 Functionality
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Application
  - 5.5.5.4 End User
  - 5.5.5.5 Form
  - 5.5.5.6 Technology
  - 5.5.5.7 Mode
  - 5.5.5.8 Stage
  - 5.5.5.9 Functionality
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Application
  - 5.5.6.4 End User
  - 5.5.6.5 Form
  - 5.5.6.6 Technology
  - 5.5.6.7 Mode
  - 5.5.6.8 Stage
  - 5.5.6.9 Functionality
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Application
  - 5.6.1.4 End User
  - 5.6.1.5 Form
  - 5.6.1.6 Technology
  - 5.6.1.7 Mode
  - 5.6.1.8 Stage
  - 5.6.1.9 Functionality
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Application
  - 5.6.2.4 End User
  - 5.6.2.5 Form
  - 5.6.2.6 Technology
  - 5.6.2.7 Mode
  - 5.6.2.8 Stage
  - 5.6.2.9 Functionality
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Application
  - 5.6.3.4 End User
  - 5.6.3.5 Form
  - 5.6.3.6 Technology
  - 5.6.3.7 Mode
  - 5.6.3.8 Stage
  - 5.6.3.9 Functionality
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Application
  - 5.6.4.4 End User
  - 5.6.4.5 Form
  - 5.6.4.6 Technology
  - 5.6.4.7 Mode
  - 5.6.4.8 Stage
  - 5.6.4.9 Functionality
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Application
  - 5.6.5.4 End User
  - 5.6.5.5 Form
  - 5.6.5.6 Technology
  - 5.6.5.7 Mode
  - 5.6.5.8 Stage
  - 5.6.5.9 Functionality

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 GlaxoSmithKline
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 Merck
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Pfizer
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Bayer
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Sanofi
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 Novartis
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Johnson and Johnson
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 Boehringer Ingelheim
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 AbbVie
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Eli Lilly
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 AstraZeneca
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Roche
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Takeda Pharmaceutical
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Bristol Myers Squibb
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Gilead Sciences
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 Amgen
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 Teva Pharmaceutical
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Sun Pharmaceutical
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Cipla
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 Mylan
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us